Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ficlatuzumab + cytarabine
- Development stage
- Unknown
- Lead developer
- AVEO Oncology
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Ficlatuzumab + cytarabine is a combination therapy under investigation for the treatment of relapsed or refractory acute myeloid leukemia (AML). Ficlatuzumab is a monoclonal antibody that inhibits hepatocyte growth factor (HGF), targeting the extracellular HGF/c-Met pathway to prevent stimulation of tumor growth, while cytarabine is a cytotoxic antimetabolite chemotherapy that inhibits DNA synthesis. This combination aims to overcome poor outcomes in patients refractory to standard cytarabine-based therapies by providing synergistic anti-leukemic activity. The regimen has demonstrated a favorable safety profile and a promising complete response rate in phase Ib clinical studies[1][3][7].
- Other names
- ficlatuzumabcytarabine
02
Targets
HGF (Hepatocyte growth factor)
Beyond the preview
Go deeper on ficlatuzumab + cytarabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ficlatuzumab + cytarabine.